Race Executes Contracts to Commence Breast Cancer Trial
Filed with ASX · · 2 pages · English
Earlier from Racura Oncology
- New Collaboration to Understand Zantrene Cardioprotection
- Race Receives Cardioprotection Ethics Trial Approval
- Race supports Study of Extramedullary AML
- Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO
- Race Appoints Damian Clarke-Bruce as CEO & Managing Director
Later from Racura Oncology
- Pause in Trading
- Race Leadership Changes
- Race Receives $1.48m R&D Tax Refund for Financial Year 2022
- Race releases cardioprotection market potential data
- Race releases complete cardio-protection data & video
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology